Adaptive Biotechnologies (NASDAQ:ADPT) Sets New 1-Year High – Time to Buy?

08 Oct 2026, 05:00 by Scott Moore · The Cerbat Gem

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $30.10 and last traded at $30.3490, with a volume of 2895 shares trading hands. The stock had previously closed at $29.84.

Wall Street Analyst Weigh In

Several brokerages recently commented on ADPT. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. Piper Sandler upped their price target on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. The Goldman Sachs Group started coverage on shares of Adaptive Biotechnologies in a research note on Tuesday, September 29th. They set a “buy” rating and a $35.00 price target for the company. National Bank Financial set a $34.00 price target on shares of Adaptive Biotechnologies in a report on Tuesday, September 22nd. Finally, TD Cowen increased their price objective on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.94.

Read Our Latest Research Report on Adaptive Biotechnologies

Adaptive Biotechnologies Price Performance

The business has a 50-day moving average of $25.94 and a 200 day moving average of $19.94. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. The firm has a market capitalization of $4.19 billion, a P/E ratio of -64.10 and a beta of 2.09.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The business had revenue of $71.55 million for the quarter, compared to the consensus estimate of $65.44 million. During the same quarter last year, the firm posted ($0.17) EPS. The business’s revenue for the quarter was up 21.5% compared to the same quarter last year. On average, sell-side analysts predict that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Francis Lo sold 26,792 shares of the firm’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $28.28, for a total value of $757,677.76. Following the transaction, the insider owned 220,867 shares of the company’s stock, valued at approximately $6,246,118.76. This trade represents a 10.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Julie Rubinstein sold 11,881 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $29.19, for a total value of $346,806.39. Following the sale, the chief operating officer directly owned 377,802 shares of the company’s stock, valued at $11,028,040.38. This represents a 3.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,419,208 shares of company stock worth $34,359,016 over the last ninety days. Insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several institutional investors have recently bought and sold shares of ADPT. Tidal Investments LLC purchased a new stake in Adaptive Biotechnologies in the 2nd quarter valued at $855,000. Integrated Wealth Concepts LLC bought a new stake in shares of Adaptive Biotechnologies in the 2nd quarter worth $46,000. Arizona State Retirement System grew its stake in shares of Adaptive Biotechnologies by 1.3% in the 2nd quarter. Arizona State Retirement System now owns 31,866 shares of the company’s stock worth $684,000 after acquiring an additional 416 shares in the last quarter. Nykredit A S bought a new stake in shares of Adaptive Biotechnologies in the 2nd quarter worth $31,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Adaptive Biotechnologies in the second quarter valued at about $754,000. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and therapeutic applications. Its technologies analyze immune-cell receptors, including T-cell and B-cell receptors, to help identify and measure immune responses associated with cancer, infectious diseases and other conditions.